Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 2:17 PM
Ignite Modification Date: 2025-12-25 @ 12:54 PM
NCT ID: NCT01959295
Description: The safety analysis population consists of 466 participants (309 in the ASP group;157 in the placebo group), excluding two participants who were randomized but never received the investigational drug. The two excluded participants were discontinued from the study before receiving the investigational drug, and therefore, they were not monitored or assessed for adverse events.
Frequency Threshold: 2
Time Frame: 29 days
Study: NCT01959295
Study Brief: Phase III Study of ASP2151 in Herpes Simplex Patients
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
ASP2151 200 mg once daily 128 None 0 309 69 309 View
ASP2151 Placebo ASP2151 placebo once daily 59 None 0 157 29 157 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Oral herpes NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA/J Ver. 16.0 View
Beta-N-acetyl-D-glucosaminidase increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA/J Ver. 16.0 View
Electrocardiogram QT prolonged NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA/J Ver. 16.0 View
Fibrin degradation products increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA/J Ver. 16.0 View
Alpha 1 microglobulin increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA/J Ver. 16.0 View
Genital herpes NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA/J Ver. 16.0 View
Nasopharyngitis NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA/J Ver. 16.0 View